Celldex Therapeutics, Inc. (NASDAQ: CLDX) has recently welcomed Denice M. Torres to its board of directors. Torres brings with her extensive leadership experience in the pharmaceutical and consumer healthcare sectors, having held various senior leadership roles at Johnson & Johnson (J&J) from 2009 to 2017.
During her tenure at J&J, Torres served as the chief strategy and transformation officer for J&J's global medical device business from 2015 to 2017, and as the president of J&J McNeil Consumer Healthcare from 2011 to 2015. Her track record includes leading the recovery of over-the-counter (OTC) brands, such as the iconic Tylenol portfolio, and creating high levels of employee engagement across all functions of the business.
Prior to her time at J&J, Torres had a successful 14-year career at Eli Lilly and Company, where she focused on marketing and business unit management. She currently serves on the board of directors of publicly traded companies 2seventybio and Glaukos and has previously served on the boards of Karuna Therapeutics, Inc., Surface Oncology, and Bluebird Bio, Inc., all publicly traded biopharmaceutical companies. She is also the founder of the Mentoring Place, a nonprofit organization offering free executive mentoring to help women achieve their career goals.
Celldex is optimistic about the significant progress it has made with barzolvolimab and its potential to set a new treatment standard in a disease where patients desperately need better options. The company sees Torres' appointment as instrumental as it advances its clinical programs and continues building the organization.
Celldex Therapeutics, Inc. is a clinical stage biotechnology company focused on the development of transformative therapeutics for patients with severe inflammatory, allergic, autoimmune, and other devastating diseases.
The addition of Denice M. Torres to the board of directors brings a wealth of operational and commercial expertise to Celldex at a crucial time in the company's development, and her appointment is expected to have a significant impact on the company's future trajectory. Following these announcements, the company's shares moved 7.48%, and are now trading at a price of $20.99. If you want to know more, read the company's complete 8-K report here.
